Abstract

We tested the hypothesis that Let-7d-3p contributes to cardiac cell protection during hypoxic challenge. Myoblast H9c2 cells and primary neonatal rat ventricular cardiomyocytes (NRVM) were transfected with five selected miRNA mimics. Both cell lines were subjected to 0.2% oxygen hypoxia. The protective effects of these miRNAs were determined by assessment of cell metabolic activity by CCK8 assay and measurement of lactate dehydrogenase (LDH) release as a marker of cell injury. Apoptosis and autophagy flux were assessed by Annexin V/7-AAD double staining and the ratio of LC3 II/I with Baf-A1 treatment, an autophagy flux inhibitor, respectively. Luciferase-reporter assay, RT-qPCR and Western blots were performed to identify the changes of relevant gene targets. Among five miRNA mimic transfections, Let-7d-3p increased CCK8 activity, and decreased LDH release in both H9c2 and NRVM during hypoxia. Apoptosis was significantly reduced in H9c2 cells transfected with Let-7d-3p mimic. Autophagy and autophagy flux were not affected. In silico, mRNAs of HMGA2, YY1, KLF9, KLF12, and MEX3C are predicted targets for Let-7d-3p. Luciferase-reporter assay confirmed that Let-7d-3p bound directly to the 3’-UTR region of HMGA2, MEX3C, and YY1, the down-regulations of these mRNAs were verified in both H9c2 and NRVM. The protein expression of HMGA2, but not others, was downregulated in H9c2 and NRVM. It is known that HMGA2 is a strong apoptosis trigger through the blocking of DNA repair. Thus, we speculate that the anti-apoptotic effects of Let-7d-3p mimic during hypoxia challenge are due to direct targeting of HMGA2.

Highlights

  • IntroductionCirculating microRNAs (miRNAs) were first detected in human plasma a decade ago

  • Circulating microRNAs were first detected in human plasma a decade ago

  • Our data suggests that Let-7d-3p exerts protective effects in both H9c2 and neonatal rat ventricular cardiomyocytes (NRVM) cells subjected to hypoxia

Read more

Summary

Introduction

Circulating microRNAs (miRNAs) were first detected in human plasma a decade ago. They have since been widely measured in both serum and plasma as promising biomarkers for various diseases. Discovery of therapeutic miRNA targets through dysregulated plasma miRNAs observed in clinical cohorts has been a productive strategy. Well-studied miRNAs in cardiovascular disease include miR-208a, miR-208b, and miR-499 which are known as potential biomarkers for acute myocardial infarction [1,2]. An antimir of miR-208a significantly suppressed myocardial hypertrophy and perivascular fibrosis in rats fed a high-salt diet [3] and miR-499 decreased apoptosis during ischemia/reperfusion [4]. The miR-208 family has displayed its potential to provide both biomarkers and therapeutic targets. We aimed to explore the therapeutic potential of miRNAs identified from clinical studies

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call